Business Context and Reporting Period
This Form 6-K filing covers the month of August 2023 for BiondVax Pharmaceuticals Ltd. (Note: The request metadata referenced "Scinai Immunotherapeutics Ltd.", but the filing text explicitly identifies the registrant as BiondVax Pharmaceuticals Ltd.). The report is filed pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding listing compliance rather than a financial results report.
Material Changes
The primary material event disclosed is the Company's status regarding its Nasdaq listing:
- Nasdaq reviewed the Company's plan to regain compliance with Listing Rule 5550(b) (Minimum Bid Price Requirement).
- Nasdaq granted an extension until October 31, 2023, for the Company to demonstrate it has regained compliance.
Guidance, Outlook, and Risks
Management Commentary: The Company announced the extension via a press release dated August 1, 2023, attached as Exhibit 99.1.
Risks and Contingencies: The Company faces the risk of delisting if it fails to demonstrate compliance with Nasdaq Listing Rule 5550(b) by the October 31, 2023 deadline. No other risks, contingencies, or unusual items are detailed in this specific filing text.
Investor Verification Checklist
- Verify the current share price to assess proximity to the $1.00 minimum bid price requirement.
- Review the attached press release (Exhibit 99.1) for specific details on the compliance plan.
- Monitor future filings to confirm if the Company meets the October 31, 2023 deadline.
- Confirm the registrant name is BiondVax Pharmaceuticals Ltd., not Scinai Immunotherapeutics Ltd.